We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Quantum Surgical Acquires NeuWave from Johnson & Johnson

By HospiMedica International staff writers
Posted on 11 Mar 2026

Quantum Surgical announced that it has acquired NeuWave Medical from Johnson & Johnson. More...

NeuWave’s microwave ablation system is used in percutaneous tumor ablation procedures, and the acquisition supports Quantum’s strategy to expand robot-assisted tumor ablation aimed at reducing cancer mortality. According to Quantum, NeuWave technology is used by physicians in more than 70% of the top U.S. cancer centers. The transaction follows Johnson & Johnson’s previously announced plan to discontinue the business and its subsequent acceptance of a binding offer from Quantum.

NeuWave Medical developed a microwave ablation system that enables physicians to treat tumors through percutaneous access. Quantum Surgical has developed the Epione system to assist physicians in treating early-stage tumors using robot-guided ablation. Johnson & Johnson acquired NeuWave in 2016 and later explored integrating its microwave ablation technology with robotic capabilities obtained through the 2019 acquisition of Auris Health.

Regulatory clearances for the robotic platform include a CE mark for abdominal, chest and musculoskeletal indications and U.S. Food and Drug Administration (FDA) clearance for the abdominal ablation indication. Quantum reported that more than 1,400 patients have been treated with the robot in Europe and the U.S. to date. Together, the microwave ablation system and the robotic platform position the combined business to support interventional oncology programs that rely on percutaneous approaches.

Following the transaction, Quantum and NeuWave will operate as subsidiaries of Precision IO Group, a newly created parent company whose largest investor is Ally Bridge Group. The group’s development efforts include a focus on remote intervention. Johnson & Johnson described the divestiture as part of an ongoing evaluation of its surgical technologies portfolio and indicated work with Quantum to support a seamless transition for customers, patients, healthcare providers, employees and other stakeholders globally.

Related Links
Quantum Surgical
Johnson & Johnson
NeuWave Medical


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The new procedure can help surgeons remove cancer while protecting major vessels and bile ducts (Photo courtesy of Adobe Stock)

Surgical Robot Makes Complex Liver Tumor Surgery Safer and Less Invasive

Tumors located in the caudate lobe of the liver present a major surgical challenge. This deep section of the liver sits close to critical blood vessels, making traditional surgical access difficult and... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.